Co-Diagnostics Introduces Its Revolutionary Coprimer Technology at MEDICA 2021

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) introduced and promoted its revolutionary CoPrimer technology and its applications to a wide audience of international attendees at MEDICA 2021.

The three-day mega event took place from November 15 to November 18, 2021, at Dusseldorf Germany with focus on areas like endoscopy and surgery devices, laboratory technology, diagnostics, prosthesis and implants, orthopedic technology and physiotherapy, imaging supplies, and medical & surgical gloves. Attendees learnt about Co-Diagnostics and its products, including its point-of-care and at-home rapid PCR diagnostics platform currently in development.

However, the highlight of Co-Diagnostics’ products presented at MEDICA 2021 was its revolutionary PCR CoPrimer technology that the company has made available at cost-efficient pricing around the world. The unique, proprietary structure of CoPrimers molecules creates reactions that are far more specific than competing PCR technologies, to better identify the presence of and distinguish between viruses, pathogens, cancer, or other attributes in agricultural or industrial applications.

One of the most important attributes of Co-Diagnostics’ CoPrimer technology is the virtual elimination of “primer-dimers,” the principal source of false positives in diagnostic testing. Primer-dimers are essentially the amplification of errors that can take place during the course of a molecular diagnostic test. These errors dramatically minimize the accuracy of the test and lead to false results and/or inaccurate diagnoses. By virtually eliminating “primer-dimers” from molecular diagnostic testing, CoPrimers assure unparalleled performance of real-time PCR molecular tests.

CoPrimers’ specificity also enables the identification of a broad spectrum of conditions in a single molecular diagnostic test procedure – known as multiplexing – as opposed to conducting discrete individual procedures. Multiplexing enables a single test to identify numerous conditions, attributes, or genetic sequences simultaneously. Multiplexing has enormous implications on cost-efficiencies and time savings in molecular testing, which could prove substantial in a medical situation.

Related Links:
Co-Diagnostics, Inc.